Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis

@article{Wu2019ComputedTB,
  title={Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis},
  author={Xiaoping Wu and Grace Hyun J. Kim and Margaret L. Salisbury and David Barber and Brian J. Bartholmai and Kevin K Brown and Craig S. Conoscenti and Jan W. de Backer and Kevin R. Flaherty and James F Gruden and Eric A. Hoffman and Stephen M. Humphries and Joseph Jacob and Toby M. Maher and Ganesh Raghu and Luca Richeldi and Brian D. Ross and Rozsa Schlenker‐Herceg and Nicola Sverzellati and Athol U. Wells and Fernando J. Martinez and David A. Lynch and Jonathan G. Goldin and Simon L F Walsh},
  journal={American Journal of Respiratory and Critical Care Medicine},
  year={2019},
  volume={199},
  pages={12–21}
}
  • Xiaoping Wu, G. Kim, +21 authors S. Walsh
  • Published 1 January 2019
  • Medicine
  • American Journal of Respiratory and Critical Care Medicine
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease severity and rate of progression. The need for a reliable, sensitive, and objective biomarker to track disease progression and response to therapy remains a great challenge in IPF clinical trials. Over the past decade, quantitative computed tomography (QCT) has emerged as an area of intensive research to address this need. We have gathered a group of pulmonologists, radiologists and scientists with… 
Using Quantitative Computed Tomographic Imaging to Understand Chronic Obstructive Pulmonary Disease and Fibrotic Interstitial Lung Disease
TLDR
The current state of the art for qualitative and qCT assessment of both COPD and fibrotic ILD are reviewed, along with the potential future role of artificial intelligence.
Thoracic computed tomography in the progressive fibrotic phenotype
TLDR
To reliably use serial CT as a marker of disease progression in fibrotic lung disease, clinicians and radiologists need to be aware of the optimal methods for identifying changes in disease extent, and understand their limitations.
Automated Computed Tomography analysis in the assessment of Idiopathic Pulmonary Fibrosis severity and progression.
TLDR
CALIPER quantification of fibrosis and vascular involvement could distinguish disease progression in treated versus untreated patients and predict the survival and changes in CALIPER-derived variables over time were significantly correlated to changes in FVC.
Applicability of radiomics in interstitial lung disease associated with systemic sclerosis: proof of concept
TLDR
The correlation of radiomics with GAP stage, but not with the visually defined features of ILD-HRCT, implies that radiomics might capture features indicating severity of SSc-ILD on HRCT, which are not recognized by visual analysis.
Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18–24-month follow-ups
TLDR
Early structural changes of 4% or more in a paired HRCT scans derived by quantitative scores can predict the progression in lung function in 1–2 years in subjects with IPF, which is critical information for timely management decision for subjects withIPF.
A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images.
TLDR
This study can serve as a reference for collecting ground truth, developing statistical learning techniques to predict progression in medical imaging and ascertained STP associations with 6-12 month changes in quantitative lung fibrosis and forced vital capacity.
Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity
TLDR
This study indicates that FRI is a superior tool than FVC in capturing of early and clinically relevant, disease progression in a regional manner.
The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis
TLDR
The utility of quantitative HRCT as an efficacy endpoint for IPF in a double-blind, placebo-controlled clinical trial setting is demonstrated and correlations were found between changes in QLF and changes in percent predicted FVC, diffusing capacity for carbon monoxide, and shortness of breath at week 26.
Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis
TLDR
In subjects with IPF, quantification of lung fibrosis extent on HRCT using data-driven texture analysis shows acceptable performance characteristics and minimal clinically important difference in the range of 3.4–6.4%.
The therapy of idiopathic pulmonary fibrosis: what is next?
TLDR
New therapeutic attempts and potential future approaches to treat IPF are summarised to aim to reduce the burden of disease.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 115 REFERENCES
Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis
TLDR
The feasibility of quantifying interval short-term changes on high-resolution computed tomography and their possible use as independent predictors of survival in idiopathic pulmonary fibrosis are demonstrated.
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.
TLDR
Extent of reticulation and honeycombing on HRCT is an important independent predictor of mortality in patients with IPF.
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
TLDR
The GAP models use commonly measured clinical and physiologic variables to predict mortality in patients with IPF and perform similarly in pooled follow-up visits.
CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.
TLDR
The uses of serial CT in clinical practice and in drug trials are examined and attention is drawn to uncertainties and challenges for future research.
Idiopathic pulmonary fibrosis: predicting response to therapy and survival.
TLDR
It is demonstrated that pretherapy pulmonary function, pathologic and radiographic parameters are different in individuals who respond to initial prednisone therapy and only HRCT imaging and pathologic fibrosis were able to reliably predict long-term survival in patients with biopsy-proven IPF.
Comparison of the quantitative CT imaging biomarkers of idiopathic pulmonary fibrosis at baseline and early change with an interval of 7 months.
TLDR
Classifier-model-derived scores (QLF and QILD), based on a set of texture features, are associated with baseline disease extent and are also a sensitive measure of change over time, which can be used for measuring the extent of disease severity and longitudinal changes.
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
TLDR
The goal of this concise clinical review is to examine and summarize the current data on the clinical course, individual predictors of survival, and proposed clinical prediction models in IPF.
Quantitative Stratification of Diffuse Parenchymal Lung Diseases
TLDR
A quantitative stratification paradigm is reported to identify subsets of DPLD patients with characteristic radiologic patterns in an unsupervised manner and demonstrate significant correlation of these self-organized disease groups with clinically accepted surrogate endpoints.
SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs.
TLDR
While imaging technologies continue to evolve, the required components of a QCT-LAS provide the framework for future studies, and the QCT results emanating from SPIROMICS and the growing number of other studies using the SPirOMICS QCT -LAS will provide a shared resource of image-derived pulmonary metrics.
Interstitial lung disease in systemic sclerosis: a simple staging system.
TLDR
An easily applicable limited/extensive staging system for SSc-ILD, based on combined evaluation with HRCT and PFTs, provides discriminatory prognostic information.
...
1
2
3
4
5
...